INOVIQ Granted SubB2M US patent for diagnostic applications
- INOVIQ (IIQ) receives a US patent that covers its SubB2M technology and provides intellectual property protection in the US for diagnostic applications
- The patent is titled “Subtilase cytotoxin B subunit mutant” and was issued to Griffith University and the University of Adelaide
- The SubB2M technology is based on an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc which is found in multiple human cancers
- The patent is titled “Subtilase cytotoxin B subunit mutant” and was issued to Griffith University and the University of Adelaide
- Shares in the company are up 14.1 per cent, trading at 44.5 cents as of 10:45 am AEST
